UAE BARQ برق الإمارات – نبضك
Shahriar Shahir Barzegar has launched the “Hayat” initiative in the UAE, introducing a structured medical framework designed to shift how obesity is understood—from a lifestyle concern to a system-level health condition requiring coordinated clinical management.
Developed as a three-month national awareness programme, “Hayat” departs from conventional campaigns by focusing on clinical literacy rather than commercial promotion. The initiative integrates medical assessment, ongoing monitoring, and structured patient pathways into a single coordinated model.
The programme is supported by global healthcare stakeholders, including Eli Lilly and True Body USA, aligning pharmaceutical innovation with device-based and clinical methodologies under a unified framework.
At its core, “Hayat” introduces a contrarian position: obesity is not primarily a weight issue—it is a systemic metabolic condition driven by multiple interconnected factors that cannot be effectively addressed through isolated interventions.
Barzegar, Founder and CEO of elegant hoopoe, stated:
“Obesity is not a weight problem. It is a system failure. Most existing approaches treat fragments—diet, medication, or devices—without connecting them. What we are introducing is a structured loop where diagnosis, treatment, monitoring, and behavioural adaptation operate as one system.”
The initiative incorporates medically guided assessments and continuous follow-up mechanisms, enabling a transition from episodic care to longitudinal metabolic management. This aligns with global shifts in healthcare, where outcomes are increasingly tied to integrated systems rather than standalone treatments.
Operating within UAE healthcare communication regulations, “Hayat” is designed to remain strictly educational, avoiding direct-to-consumer promotion of specific therapies while elevating public understanding through evidence-based messaging.
Industry observers note that the initiative reflects a broader transformation in regional healthcare models—moving toward data-driven, patient-centric frameworks that emphasise continuity, accountability, and measurable outcomes.
Early engagement within the programme indicates strong public interest in structured, medically supervised approaches to obesity, reinforcing the need for frameworks that combine clinical oversight with accessible patient pathways.
Rather than measuring success through immediate conversion metrics, “Hayat” is positioned to deliver long-term impact by redefining how obesity is perceived and managed—both clinically and socially—within the UAE.
As the initiative progresses, it is expected to contribute to a more informed healthcare dialogue while reinforcing the UAE’s position as a regional hub for structured, collaborative medical innovation.
